AUTHOR=Matsuyama Momoko , Hirai Keiji , Nonaka Hiroaki , Ueda Moeka , Morino Junki , Kaneko Shohei , Minato Saori , Mutsuyoshi Yuko , Yanai Katsunori , Ishii Hiroki , Kitano Taisuke , Aomatsu Akinori , Miyazawa Haruhisa , Ito Kiyonori , Ueda Yuichiro , Ookawara Susumu , Morishita Yoshiyuki 

TITLE=Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease

JOURNAL=Frontiers in Medicine

VOLUME=8

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.780127

DOI=10.3389/fmed.2021.780127

ISSN=2296-858X

ABSTRACT=<sec><title>Objective:</title><p>The aim of this study was to investigate the effects of elobixibat on constipation and lipid metabolism; and determine the factors associated with the effect of elobixibat on constipation in patients with moderate to end-stage chronic kidney disease (CKD).</p></sec><sec><title>Methods:</title><p>Stool frequency and serum lipid parameters were retrospectively analyzed before and after 4 weeks of elobixibat administration in 42 patients (CKD stage G3, 6; stage G4, 9; stage G5, 9; stage G5D, 18). Relationships between the change in stool frequency after initiation of elobixibat and various clinical parameters were analyzed by using linear regression analysis.</p></sec><sec><title>Results:</title><p>Elobixibat increased stool frequency from 0.5 ± 0.4 per day to 1.1 ± 0.6 per day (<italic>p</italic> &lt; 0.001) regardless of whether patients were undergoing dialysis, on concomitant laxatives, or were administered elobixibat before or after breakfast. Elobixibat reduced low-density lipoprotein cholesterol concentration (from 90.9 ± 37.2 mg/dL to 77.5 ± 34.8 mg/dL, <italic>p</italic> &lt; 0.05) and increased high-density lipoprotein cholesterol concentration (from 44.9 ± 14.3 mg/dL to 57.0 ± 25.8 mg/dL, <italic>p</italic> &lt; 0.05), but did not change triglyceride concentration. Adverse effects were observed in two patients (nausea and diarrhea). Only phosphate concentration was correlated with the change in stool frequency after initiation of elobixibat (standard coefficient = 0.321, <italic>p</italic> = 0.043).</p></sec><sec><title>Conclusions:</title><p>Elobixibat improved constipation and lipid metabolism in patients with moderate to end-stage CKD, without serious adverse events.</p></sec>